Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
NCT07449754 Cobimetinib Fumarate NRAS Mutant Melanoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
27 August 2026
NCT07449754 clinical trial report covering Cobimetinib Fumarate, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07450313 Luspatercept-AAMT Anemia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
27 August 2026
NCT07450313 clinical trial report covering Luspatercept-AAMT, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07449702 ORKA-001 Plaque psoriasis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
27 August 2026
NCT07449702 clinical trial report covering ORKA-001, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07448142 Pucotenlimab MSS/pMMR/MSI-L Rectal Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
27 August 2026
NCT07448142 clinical trial report covering Pucotenlimab, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07449481 Bevacizumab biosimilar (Innovent Biologics) Malignant Solid Neoplasm Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
27 August 2026
NCT07449481 clinical trial report covering Bevacizumab biosimilar (Innovent Biologics), Phase 2, endpoints, sponsor, geography, readout timing and developm
Latest Hotspot
8 min read
NCT07450599 Darolutamide Localized Prostate Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
27 August 2026
NCT07450599 clinical trial report covering Darolutamide, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07447817 Pacritinib Post-essential thrombocythemia myelofibrosis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
27 August 2026
NCT07447817 clinical trial report covering Pacritinib, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07447986 Recombinant human anti-CD38 momoclonal antibody(Hangzhou Sumgen) Systemic Lupus Erythematosus Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
27 August 2026
NCT07447986 clinical trial report covering Recombinant human anti-CD38 momoclonal antibody(Hangzhou Sumgen), Phase 2, endpoints, sponsor, geography, readou
Latest Hotspot
8 min read
NCT07448922 Carboplatin Bone Cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
27 August 2026
NCT07448922 clinical trial report covering Carboplatin, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07448038 Selnoflast Atherosclerosis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
27 August 2026
NCT07448038 clinical trial report covering Selnoflast, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
CTR20260775 Bevacizumab biosimilar (Chia-tai Tianqing) BRAF Mutation colorectal cancers Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
27 August 2026
CTR20260775 clinical trial report covering Bevacizumab biosimilar (Chia-tai Tianqing), Phase 2, endpoints, sponsor, geography, readout timing and developme
Latest Hotspot
8 min read
NCT07450183 Cemiplimab-RWLC Resectable Lung Non-Small Cell Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
27 August 2026
NCT07450183 clinical trial report covering Cemiplimab-RWLC, Phase 2, endpoints, sponsor, geography, readout timing and development white space.